TCF4に依存する遺伝子調節ネットワークは,メラノーマの免疫療法に対する耐性を授与する
Joanna Pozniak1, Dennis Pedri2, Ewout Landeloos3
1Laboratory for Molecular Cancer Biology, Center for Cancer Biology, VIB, Leuven, Belgium; Department of Oncology, KU Leuven, Leuven, Belgium.
Cell
|January 5, 2024
まとめ
メラノーマ細胞は,免疫反応を抑制することで,免疫チェックポイントブロック (ICB) に抵抗します. TCF4調節器を標的とした治療は,腫瘍の免疫性およびICBおよび標的治療に対する感受性を高めます.
科学分野:
- 腫瘍学
- 免疫学
- 遺伝学
背景:
- 免疫チェックポイント阻害 (ICB) に対する内在的抵抗は,メラノーマ治療における課題です.
- 腫瘍の微小環境が 治療に抵抗する役割を理解することは 極めて重要です
研究 の 目的:
- 治療先のメラノーマの細胞構造とICBの下での進化を明らかにする.
- ICBと標的治療に対する抵抗を誘発する重要な調節因子を特定する.
主な方法:
- 単細胞と空間的なマルチオミクス分析が採用された.
- メラノーマ腫瘍の微小環境内のトランスクリプトミックの風景と細胞状態を調査した.
- 重要な調節分子を標的とする遺伝的および薬理学的アプローチを用いた.
主要な成果:
- ICBでは腫瘍の微小環境によって 複雑なメラノーマのトランスクリプトミアが形成されます
- 標的治療に対する耐性に関連したメレンキマ型 (MES) 細胞は,ICBに反応しない患者で濃縮された.
- TCF4は,MES状態の主調節体として識別され,メラノサイトの分化と抗原表現を抑制しました.
- TCF4を標的とした治療は,ICBと標的治療の両方にMES細胞の免疫性および感受性を高めました.
結論:
- TCF4依存のレギュレータネットワークは,標的治療とICBの両方に対するメラノーマの抵抗に寄与する.
- TCF4の阻害は,メラノーマの抵抗を克服するための潜在的な治療戦略です.
関連する概念動画
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K


